Gao et al. proposed an MMP‐2/GSH dual‐responsive prodrug to co‐deliver a photosensitizer (Ppa) to induce ICD and an IDO inhibitor (NLG919) to remodel the tumor microenvironment (Figure 6a). This evidence concerns the gene MMP2 and neoplasm.